Home・Lista de Ações・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Abrir

SetorSaúde

218.9 -0.11

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

214.8

Máximo

222.13

Indicadores-chave
By Trading Economics
Rendimento	20M 206M
Vendas	70M 1.2B
P/E Médio do Setor	68.571 64.641
EPS	1.99
Margem de lucro	17.649
Funcionários	2,500
EBITDA	159M 304M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+71.22% upside

Dividendos
By Acuity
Próximos Ganhos	29 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-4B 37B
Abertura anterior	219.01
Fecho anterior	218.9

Sentimento de Notícias

By Acuity

100%

320 / 340 Ranking em Healthcare

Alnylam Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 20:02 UTC

News

Raymond James upgraded Alnylam Pharmaceuticals to Strong Buy with a $420 target, contributing to a notable increase in shares during Monday's session.

1 de ago. de 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

31 de jul. de 2026, 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

30 de jul. de 2026, 23:41 UTC

Alnylam Pharmaceuticals is rising in after-market hours, reflecting broader market gains. No specific news was identified to explain the price movement.

29 de jul. de 2026, 19:14 UTC

Macro Event

Correlated Moves

Alnylam Pharmaceuticals Inc shares are lower today, influenced by the Federal Reserve's decision to maintain interest rates amid economic uncertainties and sector declines.

28 de jul. de 2026, 20:02 UTC

News

Correlated Moves

Alnylam Pharmaceuticals is trading higher, benefiting from gains in the Biotechnology sector. Recent advancements in its Alzheimer's pipeline are attracting attention.

27 de jul. de 2026, 22:41 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, continuing a trend of gains over the last three sessions despite remaining below the 20-day moving average.

24 de jul. de 2026, 19:46 UTC

Correlated Moves

Alnylam Pharmaceuticals is trading higher, influenced by a rise in the Property & Casualty Insurance sector. Shares remain below their 20-day moving average.

23 de jul. de 2026, 09:51 UTC

Alnylam Pharmaceuticals shares are modestly higher in pre-market hours, trading within a narrow range since Wednesday's close. The stock remains below its 20-day moving average.

22 de jul. de 2026, 22:31 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, rebounding from earlier lows despite broader market volatility and geopolitical tensions.

21 de jul. de 2026, 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

20 de jul. de 2026, 19:26 UTC

News

Alnylam Pharmaceuticals is trading higher as it initiates a Phase 2 trial of mivelsiran for Down syndrome-associated Alzheimer’s disease, signaling progress in research.

Comparação entre Pares

Variação de preço

Alnylam Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

71.22% parte superior

Previsão para 12 meses

Média 377.24 USD 71.22%

Máximo 550 USD

Mínimo 230 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Alnylam Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para Alnylam Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

320 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.